On February 28, 2019, the US Food and Drug Administration (FDA) released a safety communication that cautioned patients, surgeons, and health care organizations about the use of robotic-assisted surgical systems for the management of breast cancer and other cancers.1 This safety communication cited concerns that evidence to support the use of robotic-assisted surgery for the management of these cancers was limited and may even be associated with shorter long-term survival compared with other surgical approaches.